3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
4
Phase 4
3
Phase 2/3
2
Phase 1
2
Phase NA
1
Phase EARLY_PHASE1
1
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
89
Leukemia
68
Precursor Cell Lymphoblastic Leukemia-Lymphoma
36
Lymphoma
26
Leukemia, Erythroblastic, Acute
19
Leukemia, Myelomonocytic, Acute
18
Leukemia, Monocytic, Acute
18
Leukemia, Megakaryoblastic, Acute
18
Congenital Abnormalities
13
Burkitt Lymphoma
13
Lymphoma, Large B-Cell, Diffuse
12
Myelodysplastic Syndromes
10
Lymphoma, Non-Hodgkin
10
Anemia, Refractory, with Excess of Blasts
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Chronic
6
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Eosinophilic, Acute
6
Recurrence
5
Myeloproliferative Disorders
5
Lymphoma, Large-Cell, Immunoblastic
5
Leukemia, Promyelocytic, Acute
5
Leukemia, Biphenotypic, Acute
5
Leukemia, Basophilic, Acute
5
Hodgkin Disease
5
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
4
Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Multiple Myeloma
4
Interventions
osimertinib
1
obinutuzumab
1
midostaurin
1
flumatinib
1
fludarabine
1
Radiotherapy
1
Oxaliplatin
1
Mitoxantrone
1
Mercaptopurine
1
Leucovorin
1
Irinotecan
1
Gemtuzumab
1
Folfox protocol
1
Fluorouracil
1
Drug Therapy
1
Daunorubicin
1
Cytarabine
1
Cyclophosphamide
1
Busulfan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasm, Residual
×
Cytarabine
×
Clear all
NCT02724163
2021-10-08
Myechild01
University of Birmingham
Phase 3
Recruiting
700 enrolled